Clinical Trial News and Research

RSS

ThromboGenics and BioInvent report positive results for anti-PlGF cancer therapeutic TB-403

ThromboGenics NV and co-development partner BioInvent International AB today reported that the results from the first Phase l study of novel anti-cancer agent TB-403 showed that it is safe and well tolerated, with pharmacokinetic properties enabling it to be developed for the treatment of cancer

3 Jun 2008

Study looks at the role of metformin as possible anti-tumor agent

Metformin, the common first-line drug for type 2 diabetes, may be effective in increasing pathologic complete response rates in diabetic women with early stage breast cancer who took the drug during chemotherapy prior to having surgery, paving the way for further research of the drug as a potential cancer therapy, according to researchers at The University of Texas M. D. Anderson Cancer Center.

2 Jun 2008

New breast cancer drug combo shrinks aggressive tumours

An international trial of a new breast cancer drug has shown the drug is able to shrink tumours caused by one of the most aggressive forms of the disease.

2 Jun 2008

Peregrine Pharmaceuticals updates on Bavituximab breast cancer study

Peregrine Pharmaceuticals, Inc. has announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

2 Jun 2008

Medarex announces preliminary data for investigational anti-PD-1 antibody

Medarex, Inc. has announced preliminary data from an ongoing Phase 1 study of MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody.

2 Jun 2008

Genta announces initial trial results for novel drug for bone disease

Genta Incorporated has announced the release of final results from the Company's Phase 1 clinical trial of G4544, a proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. Results showed that the drug was very well-tolerated, and that blood levels were achieved in a range that is known to be clinically bioactive. The data were featured in a poster session at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Saturday, May 31, 2008.

2 Jun 2008

Combination biotherapies safe, promising for melanoma patients

The combination of two different biotherapies may be beneficial for patients with inoperable melanoma, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

1 Jun 2008

University of Bristol to test effectiveness of cognitive behavioural therapy

A team of researchers, led by Dr Nicola Wiles at the University of Bristol, has been awarded £1.2 million by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme for a clinical trial to investigate the effectiveness of cognitive behavioural therapy (CBT) for patients with depression who do not respond to treatment with antidepressants.

30 May 2008

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

27 May 2008

Avoiding spleen removal for Cooley's anemia sufferers

Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in one of the world's most common blood disorders, beta-thalassemia, commonly known as Cooley's anemia. Along with sickle-cell anemia, Cooley's anemia is the most commonly inherited disease in the world, affecting many people of Mediterranean descent, and 20 out of every 100,000 African-Americans. The World Health Organization estimates that between 50,000-100,000 children are born with the disease each year.

27 May 2008

New treatments for viral and other diseases by blocking genes

The elusive goal of developing effective treatments for viral diseases such as AIDS and influenza has been brought closer by dramatic progress in the ability to interfere with viral genetic machinery. The stage was set for a coordinated European effort to accelerate research and stimulate development of new treatments against viral diseases at a recent research conference organised by the European Science Foundation (ESF).

26 May 2008

Monitoring blood flow helps improve prostate biopsies

Using a special ultrasound technique to spot areas of blood flow in the prostate gland may substantially reduce the number of unnecessary biopsies, according to a new study by urologists and radiologists at the Jefferson Prostate Diagnostic Center and the Kimmel Cancer Center at Jefferson in Philadelphia.

26 May 2008

Preservatives and food colours may be the culprits in ADHD

The suspicion that additives such as preservatives and artificial food colours can contribute to hyperactive behaviour in children has been around for years.

25 May 2008

FDA will monitor medical records of Medicare beneficiaries to identify potential prescription drug, medical device safety problems

HHS on Thursday announced the creation of a new program that will allow FDA, state agencies and academic researchers to use medical record data to ensure drugs and medical devices are safe for consumers after they enter the market, the Washington Post reports (Stein, Washington Post, 5/23).

25 May 2008

HIV patients suffer more from osteoporosis

Following the introduction of HAART (Highly Active Antiretroviral Therapy), the survival and quality of life for people infected with the human immunodeficiency virus (HIV-1) have increased in the resource-rich countries. However, with this improved prognosis an increase in long term negative disorders has been observed, namely osteoporosis (the gradual loss of bone mass).

25 May 2008

An alternative strategy for HIV vaccine research

Today, Advanced BioScience Laboratories, Inc. (ABL) and the University of Massachusetts Medical School (UMMS) report that their unique HIV vaccine formulation was effective in eliciting strong and balanced immune responses in healthy human volunteers.

22 May 2008

Unique genetic signature alerts physicians to high-risk breast tumors

A unique genetic signature can alert physicians to high-risk breast tumors that are masquerading as low-risk tumors, according to research at Washington University School of Medicine in St. Louis and collaborating institutions. Although these tumors are apparently estrogen-receptor positive - meaning they should depend on estrogen to grow - they don't respond well to anti-estrogen therapy.

21 May 2008

DNA modification seen in colorectal tumors helps predict outcomes, John Wayne Cancer Institute researchers find

An international study led by researchers at the John Wayne Cancer Institute at Saint John's Health Center has found that modifications to DNA found on multiple chromosomes in tumors can help to predict outcomes in patients with early-stage rectal cancer.

21 May 2008

New program promises to solve puzzling medical cases

A new research program in the U.S. promises to provide some answers for people suffering from mysterious diseases that have defied diagnosis.

21 May 2008

Advaxis files investigational new drug application for Lovaxin C

Advaxis Inc. completed its filing of a new investigational new drug ("IND") application with the U.S. Food and Drug Administration ("FDA"). This filing follows the successful completion of a Phase I study overseas.

20 May 2008